Successful expansion and a series of regulatory approvals have driven growth at BeiGene, Ltd. (NASDAQ:BGNE) recently. With increased stock holdings by Nine Masts Capital and BNP Paribas Financial Markets, and a reduced holding by Russell Investments Group, the company's shares have managed to cross above 200 DMA. The US FDA has sanctioned the extended use of BeiGene's blood cancer medication and permits for its esophageal cancer therapy. BeiGene's hematology portfolio took the spotlight at EHA2024, and partnerships with Survivorship and Hope as well as the $1.3bn deal with Ensem Therapeutics were also noteworthy. The new forecast after their first-quarter results indicates further growth. The company has reported substantial revenue growth in Q4 Full Year 2023 and further beat expectations in the first quarter of 2024. Their products BRUKINSA and tislelizumab have gained FDA approval for multiple indications. The company now holds a whopping 42% shares, largely owned by institutional owners, and has been awarded a $3bn Shanghai STAR listing. Some financial disclosures have surfaced potential new risks, but the company remains a \"Moderate Buy\" by brokerages.
BeiGene, Ltd. News Analytics from Wed, 14 Jun 2023 07:00:00 GMT to Sun, 19 May 2024 21:55:44 GMT - Rating 7 - Innovation 5 - Information 8 - Rumor -3
